Cell specific effects of glucocorticoid treatment on the NF- κBp65/IκBα system in patients with Crohn's disease

Gut

Volumn 45, Issue 5, 1999, Pages 693-704

  Thiele, K ^a   Bierhaus, A ^b   Autschbach, F ^a   Hofmann, M ^c   Stremmel, W ^a   Thiele, H ^d   Ziegler, R ^a   Nawroth, P P ^b,e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d Krankenhaus Bruchsal   (Germany)

^e Section of Vascular Medicine   (Germany)

Author keywords

CDAI; Crohn's disease; Inflammation; I B ; NF Bp65; Transcription factor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON CROHN DISEASE; COLON RESECTION; CORTICOSTEROID THERAPY; DRUG EFFECT; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032743142     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.45.5.693     Document Type: Article

References (48)

1. Chapple IL. Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol 1997;24:287-96.
2. Barnes PJ, Karin M. Nuclear Factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
3. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell 1996;87:13-20.
4. Verma I, Stevenson JK, Schwarz EM, et al. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev 1995;9:2723-35.
5. Collins T. Endorhelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest 1993;68:499-508.
6. Baeuerle PA, Baichval VR, NF-κB as a frequent target for immunosuppressive and antiinflammatory molecules. Adv Immunol 1997;65:111-35.
7. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates experimental colitis in mice. Nat Med 1998;2:998-1004.
8. Neurath MF, Petterson S, Predominant role of NF-κBp65 in the pathogenesis of chronic intestinal inflammation. Immunobiology 1997;198:91-8.
9. Neurath MF. Pathogenesis of inflammatory bowel disease: transcription factors in the spotlight. Gut 1998;42:458-9.
10. Schreiber S, Nikolaus S, Hampe J. Activation of the nuclear factor kappa B in inflammatory bowel disease. Gut 1998;42:477-84.
11. Ellis RD, Limb GA, Thompson RPH. NFκB in Crohn's disease. Biochem Soc Trans 1997;25:178S.
12. Ardite E, Panes J, Miranda M, et al. Effects of steroid treatment on activation of nuclear factor kappa B in patients with inflammatory bowel disease. Br J Pharmacol 1998;124:431-3.
13. Rogler G, Brand K, Vogl D, et al. Nuclear Factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:357-69.
14. Beg AA, Baldwin AS. The IκB proteins: multifunctional regulators of Rel/NF-κB transcription factors. Genes Dev 1993;7:2064-70.
15. Zabel U, Baeuerle PA. Purified human IκB can rapidly dissociate the complex of the NF-κB transcription factor with its cognate DNA. Cell 1990;61:255-65.
16. Cohen L, Henzel WI, Baeuerle PA. IKAP is a scaffold protein of the I kappa B kinase complex. Nature 1998;395:292-6.
17. Rothwarf MK, Zandl E, Natoli G, et al. IKK-gamma is an essential regulatory subunit of the I kappa B kinase complex. Nature 1998;395:297-300.
18. Bierhaus A, Klevesath M, Illmer T, et al. Ligands of RAGE mediate continuous NF-κB activation that results in persistent tissue factor induction and perpetuated endothelial dysfunction. Thromb Haemost 1997;77(suppl I):595, OC-2429 [abstract].
19. Wilckens T, De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 1997;18:418-24.
20. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and respiratory disease. Am J Respir Crit Care Med 1997;155:542-8.
21. Norbiato G, Bevilacqua M, Vago T, et al. Glucocorticoids and Th-1, Th-2 type cytokines in rheumatoid arthritis, osteoarthritis, asthma, atopic dermatitis and AIDS. Clin Exp Rheumatol 1997;15:315-23.
22. Andoh A, Fujiyama Y, Kitamura S, et al: Acute lupus peritonitis successfully treated with steroid pulse therapy. J Gastroenterol 1997;32:654-7.
23. Caesar I, Gross V, Roth M, et al. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group. Hepatogastroenterology 1997;44:445-51.
24. Geier DL, Miner PB Jr. New therapeutic agents in the treatment of inflammatory bowel disease. Am J Med 1992;93:199-208.
25. Lechner J, Welte T, Tomasi JK, et al. Promoter-dependent synergy between glucocorticoid receptor and Stat5 in the activation of beta-casein gene. J Biol Chem 1997;272:20954-60.
26. Wisniewska M, Stanczyk M, Grzelakowska-Sztabert B, et al. Nuclear factor of activated T cells (NFAT) is a possible target for dexamethasotic in thymocyte apoptosis. Cell Biol Int 1997;21:127-32.
27. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-I transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997;11:1245-55.
28. van der Burg B, Liden J, Okret S, et al. Nuclear Factor-κB repression in antiinflammation and immunosuppression by glucocorticoids. Trends in Endocrinology and Metabolism 1997;8:152-7.
29. Beato M. Gene regulation by steroid hormones. Cell 1989;56:335-44.
30. Evans RM. The steroid and thyroid hormone receptor family. Science 1988;240:889-95.
31. Caldenhoven E, Liden J, Wissinik S, et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 1995;9:401-12.
32. Scheinman RI, Gualberto A, Jewell CM, et al. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-53.
33. De Bosscher K, Schmitz ML, Vanden Berghe W, et al. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA 1997;94:13504-9.
34. Heck S, Bender K, Kullmann M, et al. IκBa-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J 1997;16:4698-707.
35. McKay LJ, Cidlowski JA. Cross-talk between nuclear factor-κB and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 1998;12:45-56.
36. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression of glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270:286-90.
37. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of IκB-a in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
38. Cordell JI, Falini B, Erber WN, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and anti-alkaline phosphatase (APAAP-complexes). J Histochem Cytochem 1984; 32:219-24.
39. Böhrer H, Qiu F, Zimmermann T. et al. Role of NF-κB in the mortality of sepsis. J Clin Invest 1997;100:972-85.
40. Bradford MM. A rapid method for the quantitation of microgram quantities of protein utilizing the principles of protein dye binding Anal Biochem 1976;72:248-54.
41. Bierhaus A, Illmer T, Kasper M, et al. Advanced glycation endproducts (AGEs) mediated induction of tissue factor in cultured endothelial tells is dependent on RAGE. Circulation 1997;96:2262-71.
42. Hofmann M, Schiekofer S, Kanitz M, et al. Insufficient glycemic control increases NF-κB binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998;21:1-7.
43. Bierhaus A, Zhang Y, Deng Y, et al. Mechanism of the TNFα mediated induction of endothelial tissue factor. J Biol Chem 1995;270:26419-32.
44. Bierhaus A, Zhang Y, Quehenberger P, et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-κB. Thromb Haemost 1997;77:772-82.
45. Kaltschmidt C, Kaltschmidt VB, Henkel T, et al. Selective recognition of the activated form of transcription factor NF-kappa B by a monoclonal antibody. Biol Chem Hoppe-Seyler 1995;376:9-16.
46. Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101;1163-74.
47. Brostjan C, Anrather J, Csizmadia V, et al. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J Biol Chem 1996;271:19612-16.
48. Vainer B, Nielsen OH. The influence of adhesion molecules in inflammatory bowel diseases. Ugeskr Laeger 1997;159:3767-71.